Cyclacel Pharmaceuticals Statistics
Share Statistics
Cyclacel Pharmaceuticals has 32.25M
shares outstanding. The number of shares has increased by 4831.06%
in one year.
| Shares Outstanding | 32.25M |
| Shares Change (YoY) | 4831.06% |
| Shares Change (QoQ) | 3377.85% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 99 |
| FTD / Avg. Volume | 1.93% |
Short Selling Information
The latest short interest is 33, so 0% of the outstanding
shares have been sold short.
| Short Interest | 33 |
| Short % of Shares Out | n/a |
| Short % of Float | 0.01% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.18 and the forward
PE ratio is null.
Cyclacel Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -0.18 |
| Forward PE | n/a |
| PS Ratio | 46.83 |
| Forward PS | 1313.1 |
| PB Ratio | -0.93 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cyclacel Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.59,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.59 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $3,583.33 |
| Profits Per Employee | $-934,333.33 |
| Employee Count | 12 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -782K |
| Effective Tax Rate | 6.52% |
Stock Price Statistics
The stock price has increased by -35.71% in the
last 52 weeks. The beta is 0.53, so Cyclacel Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.53 |
| 52-Week Price Change | -35.71% |
| 50-Day Moving Average | 5.41 |
| 200-Day Moving Average | 7.05 |
| Relative Strength Index (RSI) | 40.58 |
| Average Volume (20 Days) | 5,124 |
Income Statement
In the last 12 months, Cyclacel Pharmaceuticals had revenue of 43K
and earned -11.21M
in profits. Earnings per share was -5.21.
| Revenue | 43K |
| Gross Profit | 37K |
| Operating Income | -12M |
| Net Income | -11.21M |
| EBITDA | -12M |
| EBIT | -12M |
| Earnings Per Share (EPS) | -5.21 |
Full Income StatementBalance Sheet
The company has 3.14M in cash and 0 in
debt, giving a net cash position of 3.14M.
| Cash & Cash Equivalents | 3.14M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -439.49M |
| Total Assets | 4.09M |
| Working Capital | -2.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -7.99M
and capital expenditures 0, giving a free cash flow of -7.99M.
| Operating Cash Flow | -7.99M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.99M |
| FCF Per Share | -1.49 |
Full Cash Flow StatementMargins
Gross margin is 86.05%, with operating and profit margins of -27916.28% and -26074.42%.
| Gross Margin | 86.05% |
| Operating Margin | -27916.28% |
| Pretax Margin | -27893.02% |
| Profit Margin | -26074.42% |
| EBITDA Margin | -27902.33% |
| EBIT Margin | -27916.28% |
| FCF Margin | -18581.4% |
